A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers

Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Goff, Laura W., Cardin, Dana B., Whisenant, Jennifer G., Du, Liping, Koyama, Tatsuki, Dahlman, Kimberly B., Salaria, Safia N., Young, Ruth T., Ciombor, Kristen K., Gilbert, Jill, Smith, Stephen James, Chan, Emily, Berlin, Jordan
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2016
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://ncbi.nlm.nih.gov/pubmed/27853997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0406-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars